GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.
$121.44+1.94%
报价 2026-11-06
市值
$5.42B
EV
$6.01B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -23.6%
$43.03$158.92
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.4x | -9.50 → -10.18 | — |
| FY+32028-12 | 1.7x | -9.50 → -9.69 | — |
毛利率 -11% · TTM 收入 $167M · 基数 EPS -9.50（调整后）
电话会信号
辅助标签Q3 20262026-11-04
下调/撤回指引
指引 下调
信心 4
分析师 3
“FDA approval expected early Q1 2027 will differentiate Galleri and accelerate growth.”
原文引用（1）
- 下调/撤回指引：we are updating our guidance for the full year Galleri sales revenue growth to be 17% to 21%
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GRALGRAIL, Inc. | $5.42B | +1.9% | +23.1% | -28.1% | – | – | – | |
| NVSTEnvista Holdings Corp | $4.04B | +0.9% | +8.7% | 57.9% | 6.4x | 5.2x | 17.9x | Cheap |
| XENEXenon Pharmaceuticals Inc. | $3.79B | +4.0% | – | 0% | – | – | – | |
| DYNDyne Therapeutics, Inc. | $3.37B | +4.1% | +42.9% | 0% | – | – | – | |
| CELCCelcuity Inc. | $3.27B | +4.3% | +4666.7% | 0% | – | – | – | |
| IDYAIDEAYA Biosciences, Inc. | $3.01B | +1.9% | -84.0% | 99.5% | – | – | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.52B | -0.9% | +11.6% | 83.1% | – | – | – | |
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | $1.43B | +2.0% | – | 81.6% | – | – | – | |
| 同行中位数 | – | – | +11.6% | 57.9% | 6.4x | 5.2x | 17.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M | $40.8M | $43.6M | $36.2M | $35.5M | $31.8M | $38.3M | $28.7M |
| Gross Margin | -28.1% | 47.9% | -25.5% | -37.9% | -50% | -62.6% | -41.7% | -77.6% |
| Operating Margin | -388.9% | -332.9% | -285.4% | -346.2% | -446.9% | -482.5% | -358% | -640.5% |
| Net Income | $-110.2M | $-93.2M | $-99.2M | $-89M | $-114M | $-106.2M | $-97.1M | $-125.7M |
| Diluted EPS | -2.56 | -2.29 | -2.44 | -2.46 | -3.18 | -3.1 | -2.89 | -3.94 |
| Operating Cash Flow | $-80.7M | $-87M | $-63.8M | $-63.2M | $-77M | $-95M | $-93.5M | $-104.6M |